The Editor, We reviewed the major article by Pirellis
(1) et al regarding hepatic fi brosis progression in the presence of hepatitis C virus (HCV) infection in patients with human immunodefi ciency virus-1 (HIV-1),which reported greater stimulation by hepatic stellate cells on liver fi brosis progression in patients co infected with HIV-1 and HCV, owing to increased expression of transforming growth factor beta (TGF)-β and no relation with human platelet antigen polymorphism (1) .
Hepatitis C viral infection is a common co infection in HIV-1-infected individuals, as is hepatitis B virus (HBV), Torque teno virus (TTV), and SEN virus. Co infected patients tend to have high hepatitis C virus-ribonucleic acid (HCV RNA) levels and more severe liver disease, faster disease progression, and a higher prevalence of hepatic fi brosis (2) . Quantitative assessment of HCV RNA should be performed using reverse transcription polymerase chain reaction, which is easier and more commercially available than transcription mediated assays (TAM); however, TAM is an extremely sensitive technique.
Factors that determine HCV viral clearance or persistence in the liver remain unclear. Of acute HCV infections, 80% become chronic, with elevated alanine aminotransferase (ALT) levels, and most patients do not show physical signs of liver disease. Elevated aminotransferase levels, particularly that of ALT, are commonly observed, although one third of asymptomatic patients may have a persistently normal ALT level. Only 5% of patients with chronic HCV infection have symptomatic liver disease, which usually includes mild and insidious fatigue and dull intermittent pain in the upper quadrant, while anorexia, nausea, pruritus, arthralgia, and myalgia are less common. The disease progresses slowly, if at all, in most patients; 20% of patients progress to cirrhosis in 20 years, and progression can also lead to liver failure and hepatocellular carcinoma (HCC). A study of 53,178 recipients of HCV-contaminated lots of immunoglobulin products in Ireland in 1997 showed that 400 (0.8%) were positive in the subsequent 17 years, during the 18-25-year retrospective study period, and liver biopsy revealed mild or moderate hepatitis in 93%, bridging fi brosis in 15%, and cirrhosis in 2% of the recipients (3) . In patients with chronic HCV infection, death is usually due to cardiac or other diseases; liver-related mortality occurs in approximately 4.1% of patients with chronic HCV infection, compared with 1.3% of controls (4) . Liver histology of chronic HCV infection generally consists of intense mononuclear infl ammatory infi ltrate and some degree of fi brosis from minimal expansion of the portal tract due to cirrhosis. The fi brotic process is driven by liver infl ammation and progresses based on environmental, viral load, and host factors. Lymphoid aggregates of follicles with germinal centers are typical of chronic HCV infections. Immunohistology shows that germinal centers contain activated B cells surrounded by a network of follicular dendritic cells and a mantle zone of B cells, which in turn is surrounded by T cells. There are also fatty hepato cellular changes (steatosis) in 50% of liver biopsies, and patients infected with genotype 3 have more fat due to cytopathic effects by cluster of differentiation 8 (CD8+) T cells. Severe bile duct injury is observed in10-15% of biopsies from patients with chronic HCV and HIV-1coinfection.
Staging of chronic hepatitis requires an assessment of the degree of fi brosis using Masson's Trichrome stain. There are various other systems to grade and stage chronic hepatitis, including the modified Knodell Histology Activity Index (grade, 0-18; stage,0-4) and Ishak score (0-6), which is based on interphase hepatitis, confl uent necrosis, parenchymal injury, portal infl ammation, and fi brosis. However, the most meaningful assessment of the activity of liver diseases based on the Metavir scoring system, 1994: no fi brosis(F0),portal fi brosis (F1), little bridging fi brosis (F2), considerable bridging fi brosis (F3), and cirrhosis (F4). The inter observer variation of the Metavir system when the pathologist is well trained is low, but the sampling error often exceeds>30%; the system depends on the length of the liver biopsy obtained by a true cut needle, with at least 1.5cm required.
In an unpublished, retrospective study conducted by this author (as part of a 2003 thesis for MD in Pathology at West Bengal University of Health Sciences),cirrhosis occurred in 16-24% of patients with post-transfusion HCV infection, over a follow-up of 8-14 years. The author relied on the rate of progression from hepatitis to cirrhosis, based on the fi brosis score (Metavir stage instead of Knodell or Ischak) using the estimated number of years. Using this method, the average rate of fi brosis accumulation to develop cirrhosis was 0.133 units/year. However, the author agrees that many factors may infl uence the rate of fi brosis and proposes that most patients fall in one of three fi brosis rate groups: rapid (<20 years to develop cirrhosis), intermediate (late cirrhosis development), and slow (no cirrhosis even after 50 years). The slow group had a fi brosis rate of 0.5 units/year, which extrapolates to a mean time of 80 years to cirrhosis. Hepatic infl ammation also infl uences the rate of fi brosis; after 20 years, the risk of cirrhosis is10-13% with minimal or mild chronic HCV infection and 44-100% with moderate to severe hepatitis. With bridging fi brosis, the 5-year risk of cirrhosis becomes 58%in 10 years and 100% in 20 years (5) . The other factors that accelerate fi brosis and disease progression are regular, heavy alcohol consumption; age (>50-55 years); female gender; hispanic or white ethnicity; human leukocyte antigen DRB; HIV and other immune suppressive conditions; steatosis; severity of infl ammation; necrosis and injury; and a high iron load.
HIV-infected patients have higher HCV levels and thus a higher rate of fi brosis progression. Progression to cirrhosis is 3-fold higher in HIV-infected persons and is more common in patients with low cluster of differentiation 4 (CD4) counts. HCV viral load does not have a pivotal role, but monitoring disease progression can help to predict treatment response. The HCV genotype in that locality, as determined using restriction fragment length polymorphism, is important. Improved treatment response is observed with genotypes 2 and 3 than with genotypes 1 and 4, and patients with genotype 1 or 4 require longer treatment periods.
Hepatic fi brosis in hepatitis is a wound-healing response; myofi broblast-like cells produce hepatic fi brosis regardless of the underlying cause, and stellate cells are the key sources of these hepatic myofi broblasts. Stellate cells are actually a heterogeneous population of mesenchymal cells and are the primary site for storing retinoids and key fi brogenic cells in the liver. Stellate cell activation refers to the transformation from quiescent vitamin A-rich cells to highly fi brogenic cells in any type of hepatitis, characterized morphologically by enlargement of rough endoplasmic reticulum, diminution of vitamin A droplets, muffl ed nuclear membrane, appearance of contractile fi laments, and proliferation. Activated stellate cells are seen in large numbers at the region of greatest injury in both HCV and HIV co infection and HCV and hepatitis B confection. Large families of matrix metalloproteinases (MMPs) is responsible for liver fi brosis, of which fi broblast activation proteins such as stromelysin membrane-type metaloproteinases MT1-MMP2, MMP3 TIMP2, and plasmin release fi bril-forming type 1, type III, and type Vcollagen. Fibrosis due to chronic liver disease is related with the activity of matrix degrading enzymes, their inhibitors, and fi brogenic stimuli as well relative collagen cross linking. The biologic activity of extracellular matrix is altered, including increased cellular fi bronectin, altered integrin behavior (tripeptide sequence Arg-Gly-ASP, i.e.,GRD), cadherin selectin, upregulated tyrosine kinase receptors, discoidin domain receptors (DDR2) for activation of stellate cells that stimulate MMP and platelet-derived growth factor (PDGF), hepatocyte growth factors, connective tissue growth factors(CTGF), tumor necrosis factor-α, vascular endothelial growth factor (VEGF), and basic fi broblast growth factor (BFGF). Now, the question is howstellate cells are activated in HCV infections. Activation of stellate cells occurs in two phases: initiation and perpetuation. In the initiation phase, gene expression renders stellate cells responsive to cytokines and stimuli, while the perpetuation phase results from stimuli affecting fi brosis generation; initiation largely occurs from paracrine stimulation, and perpetuation occurs from both the autocrine and paracrine loops. Paracrine stimuli originate from neighboring cells such as the sinusoidal endothelium, Kupffer cells, hepatocytes, and platelets (human platelet antigen 1a/1b and PDGF), and sinusoidal cells release TGF-βin the pro-fi brogenic form when sinusoidal cells release adhesion molecules and VEGF. Kupffer cells stimulate MMPs and release retinoids,reactive oxygen species, and lipid peroxidase, which are strongly fi brogenic in nature. In HCV infection, steatosis occurs and increases stellate cell activation and fi brogenesis through the generation of free radicals.
The phenomenon of perpetuation requires proliferation of stellate cells, chemotaxis, fi brogenesis, contractility, matrix degradation, retinoid loss, and cytokine release; proliferation requires PDGF, VEGF, TGF-α, and BFGF signaling pathways. Fibrogenesis requires TGF-β1 and CTGF; contractility requires endothelin-1. Retinoid loss requires peroxisome,proliferated activation of receptors[agnathan paired receptors resembling antigen receptors, peroxisome proliferator-activated receptor (PPAR)-γ], farnesoid receptors, and chemoattraction for infl ammation of mono and polymorphic cells; for hepatic infl ammation, several chemokines such as CCL 2 , RANTES, CCR 5 , CxCR4, and toll like receptors(TLR3)are important (6) . CD8+T cells are more fi brogenic towards stellate cells than CD 4 + T cells, and the HIV CD 4 /CD 8 ratio is reduced more than with HCV infection alone. The TLR3 gene plays an important role in the immune response and clinical progression of fi brosis, chronicity, cirrhosis, and HCC in HCV and hepatitis B viral infections. In chronic viral infections, liver TLR3 expression is increased, leading to hepatic billiard damage and increased GGT levels in viral hepatitis. In HCV infections, putative HCV receptors are also activated in the stellate cells inducing CD 80 , LDL receptors, and C1q. The E 2 protein of HCV interacts directly with CD 81 --a stellate cell membrane receptor. Chemokines and their receptors are up regulated, stimulating lymphocyte recruitment, statuses, and apoptosis in HCV as well as accelerating fi brosis. There are many transcriptional regulatory proteins of satellite cell activation, of which PAR-δ, -β, -γ, cosine and lysine rich protein 2 (CRP-2), retinoid receptor Nek, Rappel-like factor-6, Foxf1, Lhx, and MEF2 are important (6) .
HIV1 and other hepatitis viruses: TTV and SEN virus are circular, single-stranded deoxyribonucleic acid (DNA) viruses that cause blood borne infections. Nine different SEN virus genotypes (A to I) have been identifi ed, with at least 2.5% divergence in their nucleotide sequences. The SEN virus has been isolated from the serum of HIV-positive and drug-using patients, and the SEN virus-D and V-H genotypes are the most common in patients with HIV1. TTV is also a transfusiontransmitted virus that was fi rst identifi ed in a Japanese patient in 1997; the genome of SEN virus is similar to that of TTV, and both are classifi ed within the circovirus family. According to a number of studies, the prevalence of TTV in HIV patients is slightly higher than in healthy blood donors. The TTV prevalence is higher in Spain, with a prevalence of 76% among the HIV-infected Spanish population, compared with 61% in Iran. Among HIV-infected patients, the TTV and SEN virus infection rates are higher than in healthy blood donors, suggesting that blood transfusion is the main transmission route. However, TTV is also detected in the healthy population with no history of blood transfusion, suggesting it can be transmitted in ways other than blood or injections, such as contaminated food, amniotic fl uid from TTV-positive women, breast milk, feces, saliva, bites, and a throat swab. The high prevalences of TTV DNA, SEN virus-D (24%), and SEN virus-H (33%) are due to contaminated equipment and blood products and result in chronic liver disease (64%) and liver failure in HIV-infected patients. Therefore, the presence of TTV is an independent risk factor and prognostic factor (7) .
